Arvinas to present phase 1 data for ARV-102 Parkinson's drug at conference
Tweet Send to a Friend
Arvinas Inc. (NASDAQ: ARVN) will present phase 1 clinical trial data for ARV-102, an investigational drug for Parkinson's disease, at ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
